OM:CAMX
OM:CAMXPharmaceuticals

Camurus (OM:CAMX) Valuation Check After New Long‑Acting Hypoparathyroidism Collaboration with Gubra

Camurus (OM:CAMX) just signed an exclusive collaboration and license deal with Danish biotech Gubra to develop a long acting treatment for hypoparathyroidism, a move that could quietly reshape its long term growth story. See our latest analysis for Camurus. The market seems to be pausing to reassess Camurus after a strong multi year run. The 90 day share price return of negative 13.19 percent contrasts with an impressive five year total shareholder return of 223.11 percent, suggesting long...
OM:BOL
OM:BOLMetals and Mining

The Bull Case For Boliden (OM:BOL) Could Change Following Aitik Tailings-Management Upgrades – Learn Why

ABB has recently upgraded the electrification and automation systems at Boliden’s Aitik copper mine, enhancing tailings storage, water recycling, and real-time monitoring to support a safer, more efficient expansion of one of Europe’s key tailings facilities. This investment strengthens Boliden’s push toward zero-harm, standards-aligned tailings management, underscoring how operational scaling at Aitik is being tied closely to tighter environmental controls and more sustainable copper...
OM:SAND
OM:SANDMachinery

Sandvik (OM:SAND) Valuation Check After Major Mining Equipment Wins at Eldorado Gold and Northern Star

Sandvik (OM:SAND) has secured two sizeable mining equipment deals, including battery electric vehicles for Eldorado Gold's Lamaque mine and a major underground fleet order from Northern Star Resources, reinforcing demand for its mining solutions. See our latest analysis for Sandvik. These back to back mining wins arrive as Sandvik's share price trades around SEK 295.7, with strong upward momentum reflected in a roughly 47% year to date share price return and a robust multi year total...
OM:BETS B
OM:BETS BHospitality

How Investors Are Reacting To Betsson (OM:BETS B) Expanding Its €40m Share Buyback Program

Earlier in December 2025, Betsson AB repurchased 126,400 of its own series B shares under a Board-approved share buyback program of up to €40 million, running from October 2025 to April 2026 and carried out in line with EU regulations. Following these transactions, Betsson held 2,154,922 series B and 2,747,433 series C shares, underscoring an active capital management approach aimed at reinforcing its market position and potential shareholder value. We’ll now look at how Betsson’s €40...
OM:BHG
OM:BHGSpecialty Retail

European Stocks Priced Below Estimated Intrinsic Value

As European markets navigate a mixed landscape with the pan-European STOXX Europe 600 Index ending slightly lower, investors are keenly observing economic indicators and central bank policies that could influence future growth. In this environment, identifying stocks priced below their estimated intrinsic value can offer potential opportunities for investors seeking to capitalize on market inefficiencies.
OM:NIO
OM:NIOMetals and Mining

European Penny Stocks To Watch In December 2025

As the European markets navigate a mixed landscape with some indices gaining and others slipping, investors are closely watching central bank policies and economic indicators for cues. Penny stocks, though often considered a niche investment area, continue to offer intriguing opportunities for those looking beyond the larger market names. These smaller or newer companies can present growth potential at lower price points, particularly when they demonstrate strong financial health and solid...
OM:SAAB B
OM:SAAB BAerospace & Defense

Saab’s AI-Driven 3D-Printed Fuselages Could Be A Game Changer For Saab (OM:SAAB B)

Divergent Technologies and Saab recently announced the delivery of initial 15-foot autonomous aircraft fuselages jointly designed and built using Divergent’s fully digital, AI-driven, fixtureless manufacturing system. This project creates one of the largest laser powder bed fusion flight structures to date, underlining Saab’s push into advanced, flexible defense manufacturing for future autonomous platforms. We’ll now explore how Saab’s use of Divergent’s AI-driven, additive manufacturing...
OM:BIOG B
OM:BIOG BBiotechs

Undiscovered European Gems for December 2025

As the European markets navigate a landscape marked by mixed performance in major indices and cautious economic outlooks, investors are keenly observing the potential impacts of interest rate shifts and economic resilience. In this context, identifying promising small-cap stocks that demonstrate strong fundamentals and adaptability to changing conditions can be particularly rewarding.
OM:NEXAM
OM:NEXAMChemicals

3 European Penny Stocks With At Least €90M Market Cap

As the European markets navigate mixed performances, with Germany's DAX showing gains while other major indices like France's CAC 40 and the UK's FTSE 100 experience slight declines, investors are exploring diverse opportunities. Penny stocks, despite their somewhat outdated name, remain a relevant investment area for those interested in smaller or newer companies that may offer surprising value. By focusing on penny stocks with strong financials and potential growth trajectories, investors...
OM:CLA B
OM:CLA BFood

Undiscovered Gems in Europe for December 2025

As European markets navigate a complex landscape of mixed economic indicators and potential monetary policy shifts, the pan-European STOXX Europe 600 Index has seen slight declines, reflecting broader market uncertainties. Amid these dynamics, identifying promising small-cap stocks requires a keen understanding of how they can leverage resilience and innovation to thrive in challenging environments.
OM:SOBI
OM:SOBIBiotechs

Is Swedish Orphan Biovitrum (OM:SOBI) Still Undervalued After Its Recent Share Price Pullback?

Swedish Orphan Biovitrum (OM:SOBI) has quietly delivered strong multi year gains, and with the share price easing about 3% over the past month, investors are starting to reassess whether the current pullback offers value. See our latest analysis for Swedish Orphan Biovitrum. At around SEK 329.6, the recent 7 day and 30 day share price pullback sits against a still solid 90 day share price return of 18.1% and a five year total shareholder return above 100%. This suggests longer term momentum...